TrovaGene Inc Share Price Nasdaq
Equities
US8972383090
Biotechnology & Medical Research
Sales 2024 * | 390K 30.69M | Sales 2025 * | 66.67K 5.25M | Capitalization | 158M 12.46B |
---|---|---|---|---|---|
Net income 2024 * | -45M -3.54B | Net income 2025 * | -57M -4.49B | EV / Sales 2024 * | 406 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2,375 x |
P/E ratio 2024 * |
-3.62
x | P/E ratio 2025 * |
-3.34
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on TrovaGene Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 03/03/13 |
James Levine
DFI | Director of Finance/CFO | 53 | 11/07/21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 10/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 21/04/20 |
Gary Pace
BRD | Director/Board Member | 76 | 21/04/20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 03/03/13 |
1st Jan change | Capi. | |
---|---|---|
+41.79% | 54.04B | |
+45.83% | 41.96B | |
-0.56% | 41.92B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+29.60% | 12.28B | |
+24.91% | 12.19B |